FLT3 and acute myeloid leukemia: A pooled analysis of patients with FLT3-mutated AML treated on prospective clinical trials with azacitidine + venetoclax or azacitidine alone was conducted to clarify the clinical outcomes in this population with these commonly used lower-intensity regimens [13].